A Phase 4 interventional study of Rapamune in Chronic Kidney Failure, Graft vs Host Disease and Kidney Transplantation, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer. Completed. Open to participants aged 13 Years and older. Per ClinicalTrials.gov, last updated 2009-08-18.
Sponsored by Wyeth is now a wholly owned subsidiary of Pfizer (part of Pfizer) · Phase 4 and Interventional
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies testing sirolimus in Kidney Failure, Chronic — none open to participants now, none under way, none of them phase 3. Sirolimus · Kidney Failure, Chronic.
Among the 12 studies testing sirolimus in Kidney Failure, Chronic, this one has the largest enrollment, is one of 2 in phase 4, and was the 4th registered.
2,112 studies on the registry are indexed under Kidney Failure, Chronic; 274 are open to participants now.
Browse Kidney Failure, Chronic studies →None of the 12 studies testing sirolimus in Kidney Failure, Chronic is open now. The open studies under Kidney Failure, Chronic, anywhere →
Sirolimus: first FDA approval 1999 (RAPAMUNE), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →
Of the 169 Kidney Failure, Chronic studies recruiting now, 109 (64%) set no upper age limit and 32 (19%) stop at 75 or younger; 18 take children under 18; 22 take healthy volunteers.
This study: 13 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 4 · Phase 3 4 · Phase 4 2
First in 1999; this study’s year is marked.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 484 is above the median of 57 across 1,572 interventional studies indexed under Kidney Failure, Chronic.
Median enrollment 80 across the 12 interventional studies. Of the 11 that completed or were terminated, 5 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 12 have an industry lead sponsor. The 8 most frequent:
This study is registered under Wyeth is now a wholly owned subsidiary of Pfizer, one of the names counted as Pfizer. Under that name alone:
Wyeth is now a wholly owned subsidiary of Pfizer is the lead sponsor of 484 studies on the registry; none are open to participants now.
10 studies in Kidney Failure, Chronic by Pfizer: none open now, none under way, none of them phase 3. Of 10 finished, 6 (60%) have results posted.
Among the 10 studies in Kidney Failure, Chronic by Pfizer, this one is the 2nd largest by enrollment, is the only one in phase 4, and was the 1st registered.
Pfizer’s Kidney Failure, Chronic studies by the year they started, since 2003.
None of the studies under way reaches primary completion within a year.
Among the 12 studies testing sirolimus in Kidney Failure, Chronic, from their registry updates:
Among Pfizer’s 10 in Kidney Failure, Chronic:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The incidence of efficacy failure at 12 months between two regimens.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
No study locations are listed for this record.
This study is completed, as verified in Aug 2009. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Sirolimus
Wyeth is now a wholly owned subsidiary of Pfizer →